Irvine, California – Lionheart Health, Inc. working with Leonhardt Ventures LLC, an innovation leader focused on developing unique solutions to aging, announces the filing of a new provisional patent application on a bioelectric enhanced PRF and Klotho Expressing Stem Cell Combination Therapy for regenerating organs including skin, hair, joints, hearts, bladders, livers, kidneys, pancreas, eye vision, ear hearing, brains, lung and more.“The filing of this new provisional patent application is another pivotal component of our broad strategy of expanding our already list of patents. Importantly, this filing is timely as we look to demonstrate the potential broad application of our technologies for delaying and reversing many aging related ailments”
Backed by in-vitro bioelectric PRF protein expression data, the provisional patent application displays the potential effectiveness of bioelectric enhanced Super PRF (includes slurry of autologous muscle cells) combined with klotho expressing stem cells. The bioelectric enhanced PRF has up to 300% higher level of key regeneration promoting proteins.
“The filing of this new provisional patent application is another pivotal component of our broad strategy of expanding our already long list of patents. Importantly, this filing is timely as we look to demonstrate the potential broad application of our platform bioelectric protein expression technology,” said Brian Lasater, Chief Technology Officer of the Company.Lionheart Health, Inc. is currently completing pre-clinical studies with intent to enter clinical studies for this combination therapy first in treating knee osteoarthritis. Plans are in place to take it also to clinic soon for treating bladder dysfunction and kidney failure.“We have demonstrated in our R&D lab the ability to dramatically increase the volume of regenerative proteins by stimulating muscle cells and PRF with the precisely correct bioelectric signaling sequences. This is especially true of klotho, PDGF, SDF1, VEGF, eNOS, follistatin and S100a all highly potent regeneration promoting proteins.” stated Dr. Jorge Genovese VP of Bioelectric Regeneration Research at Leonhardt Ventures LLC and Lionheart Health, Inc.About Leonhardt Ventures LLC: An innovation leader in medtech and biotech product development since 1982 http://www.leonhardtventures.com. More than 600,000 patients have been treated with Leonhardt inventions.About Lionheart Health, Inc.: A 2022 spin out of Leonhardt Ventures LLC focused on commercializing Leonhardt inventions utilizing bioelectric protein expressions. See http://www.lionhearthealthstim.com and http://www.lionheartlongevity.com
